Combined use of antibiotics and PPIs tied to increased risk of Clostridioides difficile infection Medha Baranwal29 Jan 2024 11:30 AM ISTSweden: A recent study published in the Journal of Antimicrobial Chemotherapy revealed an increased risk of Clostridioides difficile infection (CDI)...
Novel Antibiotic Omadacycline Shows Potential for Treating C. difficile Infection Dr Riya Dave13 Jan 2024 9:30 AM ISTA recent phase 1 clinical trial has uncovered promising findings regarding the use of omadacycline-an aminomethylcycline tetracycline-as a potential...
Doxycycline may Reduce Risk of Clostridioides difficile Infection in community acquired Pneumonia patients Dr Riya Dave21 Dec 2023 8:00 AM ISTA recent retrospective analysis conducted in Veterans Affairs Hospitals across the United States suggests that doxycycline, a commonly used...
Clostridioides difficile Infection Exacerbates COVID-19 Outcomes Jacinthlyn Sylvia18 Sept 2023 11:30 AM ISTA recent study conducted using the extensive National Inpatient Sample (NIS) database has shed light on a concerning association between...
Fidaxomicin vs Metronidazole: which is better Treatment for Clostridium difficle Infection? Dr.Niharika Harsha B11 Sept 2023 8:00 PM ISTA recently conducted study has delved into the world of healthcare economics, specifically addressing the significant implications of Clostridioides...
FDA approves first pill for faecal transplants to prevent recurrent Clostridioides difficile Infection Dr. Kamal Kant Kohli29 April 2023 11:00 AM ISTUSA: Vowst (fecal microbiota spores, live-brpk), the first-ever oral live microbiota, has received the US Food and Drug Administration (FDA) approval...
Vonoprazan effective against Clostridoides difficile infection: Study Jacinthlyn Sylvia16 March 2023 9:15 AM ISTVonoprazan as safe and effective as proton pump inhibitors (PPIs) against Clostridioides difficile infection (CDI) suggests an article published in...
USFDA approves first Fecal Microbiota product REBYOTA from Ferring Pharma Ruchika Sharma1 Dec 2022 12:15 PM ISTREBYOTA is a pre-packaged, single-dose 150 mL microbiota suspension for rectal administration.
Fidaxomicin better than Vancomycin for treating C. difficile Infection: Study Jacinthlyn Sylvia4 Oct 2022 11:30 AM ISTIn terms of clinical cure rates and adverse event rates in Clostridioides difficile infection (CDI) patients, fidaxomicin (FDX) is equivalent to...
Oral capsule and colonic administration both demonstrate similar advantages for C. difficile infection Dr. Kamal Kant Kohli22 Sept 2022 8:30 PM ISTMinnesota: In a prospective trial published in the Journal of Clinical Gastroenterology and Hepatology, fecal microbiota transplantation (FMT)...
Fecal Microbiota Transplantation Might Prevent Clostridioides difficile infection in IBD Patients MD Bureau25 Dec 2021 9:00 AM ISTClostridioides (formerly Clostridium) difficile is a Gram-positive, anaerobic, spore-forming opportunistic pathogen and is the leading cause of...
